<SEC-DOCUMENT>0001193125-13-146083.txt : 20130408
<SEC-HEADER>0001193125-13-146083.hdr.sgml : 20130408
<ACCEPTANCE-DATETIME>20130408170037
ACCESSION NUMBER:		0001193125-13-146083
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130403
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130408
DATE AS OF CHANGE:		20130408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		13748889

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d518287d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 OR 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>The Securities Exchange Act Of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): April&nbsp;3, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>BRISTOL-MYERS SQUIBB COMPANY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-1136</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22-0790350</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other&nbsp;Jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>345 Park Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY, 10154 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Office)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (212)&nbsp;546-4000 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see </I>General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;3, 2013, Elliott Sigal notified Bristol-Myers Squibb Company (the &#147;Company&#148;) that he will retire from his position as Executive Vice President and Chief Scientific Officer and as a member of the Board of Directors of the Company
effective June&nbsp;30, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;7, 2013, the Company
announced that Francis Cuss, Senior Vice President, Research, will be promoted to Executive Vice President and Chief Scientific Officer, effective July&nbsp;1, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Cuss, 58, joined the Company in 2003 as Senior Vice President, Drug Discovery. From 2006 to 2010 he served as Senior Vice President, Discovery and Exploratory Clinical Research, and since 2010,
he has served as Senior Vice President, Research. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no arrangements or understandings between Dr.&nbsp;Cuss and any
other persons pursuant to which he was selected as an officer. There are no related party transactions between the Company and Dr.&nbsp;Cuss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective July&nbsp;1, 2013, and in connection with Dr.&nbsp;Cuss&#146;s promotion to Executive Vice President and Chief Scientific Officer, Dr.&nbsp;Cuss will receive the following compensation:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">An annual base salary of $875,000; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">An annual discretionary incentive payout under the Company&#146;s Senior Executive Performance Incentive Plan or any successor annual bonus plan based
on a target bonus opportunity of 100% of his base salary based on the attainment of one or more pre-established performance goals established by the Board or a Board Committee; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A long-term performance award valued at $500,000 on the first business day of the month following his becoming Executive Vice President and Chief
Scientific Officer. The terms and conditions of the award will be substantially similar to the Company&#146;s standard form of Restricted Stock Units Agreement with five-year vesting under its 2012 Stock Award and Incentive Plan (&#147;2012
Plan&#148;); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participation in the standard annual long-term incentive award program, including eligibility to receive grants of performance share units and market
share units, the terms of which will be based on the Company&#146;s standard forms of equity award agreements under the 2012 Plan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change-in-control and severance benefits in the event of involuntary termination without cause in the same form as provided to the Named Executive
Officers of the Company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the press release announcing Dr.&nbsp;Sigal&#146;s retirement effective
June&nbsp;30, 2013 and Dr.&nbsp;Cuss&#146;s appointment as Executive Vice President and Chief Scientific Officer effective July&nbsp;1, 2013 is attached to this report as Exhibit 99.1 and incorporated herein by reference. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exhibits. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated April&nbsp;7, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRISTOL-MYERS SQUIBB COMPANY</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April&nbsp;8, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sandra Leung</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sandra Leung</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel and Corporate Secretary</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated April 7, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d518287dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g518287g59r74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bristol-Myers Squibb Announces Appointment of Francis Cuss as Executive Vice President and Chief
Scientific Officer, Effective July&nbsp;1; Elliott Sigal Plans to Retire </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(NEW YORK, April&nbsp;7, 2013) &#150;
Bristol-Myers Squibb Company (NYSE: BMY) today announced the appointment of Francis Cuss, MB BChir, FRCP, 58, as executive vice president and chief scientific officer, effective July&nbsp;1 after Elliott Sigal, M.D., Ph.D., 61, retires.
Dr.&nbsp;Sigal has served as the company&#146;s chief scientific officer since 2004 and on the company&#146;s Board of Directors since 2011. He will retire from both positions effective June&nbsp;30, 2013. Drs. Sigal and Cuss will continue to work
together until that time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Francis is a strong and collaborative leader with broad experience in both discovery and
development,&#148; said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. &#147;He has been a key member of our productive R&amp;D team who, under Elliott&#146;s leadership, has delivered our strong portfolio and pipeline.&nbsp;As
our company embarks on the next phase of pipeline execution, this is a natural time for Francis to lead our R&amp;D team.&nbsp;Having&nbsp;worked closely with Francis since 2010 when I invited him to join my Senior Management Team immediately after
becoming&nbsp;CEO, I know that he can ensure the continuation of both the leadership and strategy that have been the hallmarks of our success.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;Elliott has been a key leader in the development and execution of our company&#146;s strategy to become a BioPharma leader,&#148; said Andreotti. &#147;He and his team have become one of the most
productive and innovative R&amp;D organizations in the industry. Elliott has had a significant impact on the transformation of our company and, most importantly, on the patients we serve. I am grateful for the many things that Elliott and I have
been able to accomplish together.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I am honored to have the opportunity to lead this talented R&amp;D team to
fulfill our mission and find new ways to discover, develop and deliver innovative medicines for patients with unmet medical needs,&#148; said Cuss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Cuss has a strong medical background, and broad experience in both research and development. Prior to joining Bristol-Myers Squibb, Dr.&nbsp;Cuss led teams in the successful development and
approval of several blockbuster medicines. At Bristol-Myers Squibb, Dr.&nbsp;Cuss </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has a proven track record of leading our company&#146;s research organization to become among the most efficient in the industry. He has built a high-performing team, and has delivered a
differentiated and innovative early and mid-stage pipeline including making significant contributions in the advancement of our company&#146;s Hepatitis C and immuno-oncology portfolios, particularly PD-1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Cuss joined Bristol-Myers Squibb in 2003 as senior vice president, Drug Discovery, adding responsibility for Discovery Medicine
and Clinical Pharmacology in May 2006. Under Dr.&nbsp;Cuss&#146; leadership, Bristol-Myers Squibb has consistently been rated a leading research organization based on cycle time, success rates and costs, having increased discovery output while
maintaining a flat operating budget. Dr.&nbsp;Cuss and his team successfully integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance.
Dr.&nbsp;Cuss became a member of the company&#146;s Senior Management Team in 2010. Prior to joining Bristol-Myers Squibb, Dr.&nbsp;Cuss spent 14 years at Schering-Plough and three years at Glaxo, holding positions of increasing responsibility in
discovery, clinical research and medical affairs in both the U.S. and Europe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to joining the pharmaceutical industry,
Dr.&nbsp;Cuss was a practicing physician and held several academic appointments, including as adjunct associate professor at Jefferson Medical College at Thomas Jefferson University in Philadelphia. Dr.&nbsp;Cuss received his medical training in the
U.K. and holds medical degrees from Cambridge University. He is also a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Sigal joined Bristol-Myers Squibb in 1997 as vice president of the newly created department of Applied Genomics. He served as senior vice president, Early Discovery and Applied Technology, head
of Drug Discovery&nbsp;&amp; Exploratory Development, and senior vice president, Global Clinical and Pharmaceutical Development, before being appointed chief scientific officer and president of R&amp;D in 2004. Dr.&nbsp;Sigal has been a member of
the company&#146;s senior management team since 2001, was appointed executive vice president in 2006 and was elected to the Board of Directors in 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a physician, Dr.&nbsp;Sigal&#146;s commitment has always been to the patients who have and will benefit from the new medicines he and his team have helped the company deliver. Under
Dr.&nbsp;Sigal&#146;s leadership, 14 new products have been brought to market including medicines to treat diseases including cancer, serious mental illness, HIV/AIDS, hepatitis B, rheumatoid arthritis, solid organ transplant rejection, and
cardiovascular and metabolic diseases. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There will be a conference call on April&nbsp;8, 2013, at 9 a.m. (EDT) when company
executives will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast at http://investor.bms.com or by dialing 913-312-0389, confirmation code 6437563. A replay of the call will be
available beginning at noon (EDT) on April&nbsp;8 through noon (EDT) on April&nbsp;23, 2013. The replay will also be available through http://investor.bms.com or by dialing 402-280-9013, confirmation code: 6437563. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Bristol-Myers Squibb </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information,
please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bristol-Myers Squibb </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Media: Jennifer Fron
Mauer, 609-252-6579 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">jennifer.mauer@bms.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investors: John Elicker, 609-252-4611 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">john.elicker@bms.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g518287g59r74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518287g59r74.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*P#A`P$1``(1`0,1`?_$`*@``0`#``,!`0$`````
M```````'"`D$!08#`@H!`0`#``,!`0`````````````%!@<!`P0""!````8"
M`@$#`@0$!@,``````0(#!08'!`@`$1(A%0DQ$T$B%!8R(Q<887&A4C0E\4(U
M$0`!`@4"!`,$!P4&!P`````!$0(`(00%!C$200,5!U%A(G&1,A3P@:&QP246
MT?$3)!?A0E)R-$62TN(C=#55_]H`#`,!``(1`Q$`/P#^_CB$>!F,VB,`8UY-
M,Y$V1M@;CMILQV<\HF`W)J/.2#.UE.JH8"!]Y<Q2@'?0&]?I].^EI:NLK/DZ
M)JN\/P^B"/)5W*DM=&:RM*-E.(@C.T%,S9BQ9%#GV7RUBR_^*[,-8V@XMP_Y
M*(P\P<FZG%[W25'RMPY08_P.W[PYP^V*U2Y?CE91_/47.>6_Y*[_`)(_#WMQ
M0,4<&AFE\Y&&.;\#G[.E-HA-(2#@+,<`R`3/)HY@ATF`^7D(@(AZ@'?ISBCQ
M#)*YNZW4>]OD1[?+QC[JLZQBCK/D:VL`?]?T_=%H.5Z+;#B$.(0XA#B$.(0X
MA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$9T;)$B=G
M(.*$XS&C%J.M9_7T:-[KG)-K9+[3?9O&P?$P,4J9E"0J-J>"8@7_`.QGY@&_
M,W>M]Q9]=9WAMN'YW7MDDT8DD\W.&@W2`4`F,OS%E#=075X2QV\S\S_8)<(A
MF/X#A56195;)2!^AEIP?.;'JOINP8K2/[^JU]>V*.&4?F)9-*+R!.)$?C@!C
M%`K,42B7TP/S3M61>/DKQS`MA<=KFZAK@"2I0%#HI0'TD#U3K=#R6X_RZRS<
MHK?;>`0=%!1/VI[](\E9T(@4]3OE]6+BY-1TK#),PY\LE3N=X=++M=5F*F`/
M[V_@=22))J'*4S9UXE`<$[7T1P'J2M%RK+(VBM_*(Z[<BU`DF,5`T,")($*4
M29,FAL15^MMFO!O%:6_D5N59C\QN0!*DDSX"6I(01HM4.4##D.U2Y6<FXDAR
M+:]01T5SB.)9#5KSYIQLZ1TCB!3Q$Y3,R@=B91+#PW$__/`I<PNI%21=RU-Y
M*H$&Y%=+BLRJNFH)41L=F2D:;*TMWM!V_P#@2#9R0_W9:_?9#K[:?28!Z!Z!
MW_KR"BS1AG0NY'R`[6RS:!MJB"ZMU+CZV6,\U6>(6(I9D^=YG,8^,@*HVA.8
MR_Q*/L3$J=G`H.?LJA1$>@)Z<VV_X'VQPJ@LK[U6WRX&Z,)+FAK4TFCE(,U`
M((E.>OYWQ;.^YF9U-XY=EH[+;V6P@#<2255`4U7CIXA`)7:^/W;X-V=?TK8S
MX6$`E+%,I/7D\BI<TKJV8$RC/Z<'HK&[G]<IC_[,HIG'L>OR^G7K2^X^''M]
ME!L+ZK>T-!X3\M=5"K(3'MC0>V&=_P!0<9%^^4-OF9?:O#]HXQ+5[W++*?+5
MA(C1EA7.-A6C%Z\>P@?LP!6S$^G$%9[)?U!?']K1@OJKXAZ>7\7J`C!V*PTE
MV^:^;KFT!#%!<%).DB-/,^K732)_)L@K;&:3Y*B=<#6\Q"A1.,Y<=?Q58LYR
M"BT17BO=A:NM&SKII^'NN2X337YQB#+96,9L=<)L:W6;,@OC$W(.ZZ9,=X.I
MBB(G!/L"^7T'U[EKGC5YM%HHKQ<`UK+B"6SF@0*GA,:$R(7:2D5JU9+9[K=Z
MRRT!)?;B`Z4I_7]//6+#\B8LL9Y:Q[56'<FRNYM%SV#QF(8&L<FKEDB^<Q2-
MP?W.3-\]8GV0X[N^%,DF1%11@+@"0H?0YS?CUUH&58;1V#&++>Z&J/,ZFUQT
MD"U!M*Z*245=#.49=B&:7?(,RO.+UU(&-MI`$]57QUA\BNS%MZA:ZO=\U?$(
M+/BP]V8<:41>6YSU@9[BW25]8XVT)Q\&$JHG?AD#V3T,42B4P=!W].CMEC%F
MS?)QBUYK',+Q(M`606:@@2&I":"11>_NIF%WPG&3DEFI`\@H=V@!\4FFOB==
M8E[7O9^O+_UHAFS[&Y8C%#'V&&E$A]PR2@G#C,(*$G32\&(!Q36B>2UYB:@F
M_P!@FZ`!`>1>3XS78[DM7C'/&YS'D`^*_#P&H(!1`J\(G,8S"S9#B%)DUO)%
MF<Q9\$D?=^`BEGQR_('8V^4^V`<4J[B,`INH9,G%HT.5FO)[0D`OALG)CSK(
MV50HQYB3,PM)C"4IC&\C"!>@\N7?N?VZM/;NCH6\RL>^^W)I)D-HVH/\RN/P
M@EQEPBA=JNY]U[D5M811MM]BMX`XZE3MGX#5):HJ1L%S(XVN'$(<0AQ",YOD
M*W'S--:LA,BC,-:YI8-L6E$ZAKW$D;P,9A+;)9,9<$'><2`IO/%C6,5,?(2!
MV(B'KZ<T#MSA+L[NM725;OX=EH&!ST"NTX`@\2AD=$12",L[FYR_`+125-+1
M_P`2^7#F?(M6:%"?#@A0K]8"QTT"L+Y`(E>=50._JVH&34W8&%*2/%FT.A9G
ME!):R,RKRPM4B8YVHL+7',H&\03<Q,8IU3%*`$/Z\YN5L[85&,UE;C=9>A>P
M00VX[`"U9EH:J<4'I]0F$*QQ:;EW.HLCH[=D])9C9:U0#;]Y1R$A2Z9]QDH6
M21IES/HU2'$(K1L;<<OI&*QB10NB;$OAQ?K&B<)SH[7`-'N<?9Y"NJ7(G#T.
M0``6-10I?YW0>0>0=CZ@89S&[+17^N^2KJYEMY8:3N=,?>!I,S'L14K63WRM
ML-!\Y0T3K@\G1O[N/LB`JVVFG<PWSO34N0P6.,41K&GX?:T5EK1)G-XD,I))
MI$1FZ>D$R8^(P%`2]$;Q`ZOT-Y&#D_=L2HZ3`+?FE'5%PN3R-$V[0Z<YH-NN
MA64C%8MF8W6J[DUN%U-*T,H+0'*`/4I:A5#\0,B)C7V_O=;:NQ-75]:B0Z!1
M>4L%U[&5S1\G>9#)7!O=HL,_>12QLYC82XY22!0Z"&68I/=$@3,3H`$O7';_
M``ZCRX7IU;5EHM=F=<."$-*'ZM"FOU1Y^XF;W3#'69EOI`\W*\MM_P#Q*0?K
M0C]ZC1'E$C5(<0B"K]<9@QT[:#K7P9H39N@$KSXT5G:P>W11Y39<A9,S0R"_
MQ@KL]%4+YX_:Z?\`,Z`!['Q&5L?(H:F[T='7R:7@3,D5"-#KHGVA8@<GJ*^E
MQRL?8TZQME*:^/N\XRRU[S+EE,?:A:JV@%JRIKBJ?ZQ2T%6AMDT?:I,=4KY]
MNJC62H@P*2P43"=T[-[R3HQW-R*)1YK.5FQ4=QG6OMQ02`<1J=2T>)^%?-.,
M8QC#<IK*!!1=2)_^DB^X_L_&*^W0XGQ)9&6V>.3K5E?LJCOAN&;2B8V.W1%Y
M*`)^RL;Z:3%-'A"1IE`&EH][]B*X9O0MH=<L^/-9\D7VYHN.0.*GJ00DH&J>
M)*``+P`&B14L@+OG@VO/3<?'_P`V?G+ZR3[5B8-:E+9=&*/8#/`(;8+XQ&>,
M]JCD]S&:,&9$Q=U2B[L=5IV6I&T"?F[!Y3,[*`<``I@[Z&*RT6.DKOY^M?;2
M?\+220)H2T$A%43&IB;PPWJIH2ZCHVW%H\2`GOE'N8\\6]&]BZ68F&*L46$9
MV]M$P@E:92$TC+*T/[&?(FB#^HK9*:5<)IF9`="-;44W7MV`)FPQNQ&&-%8J
MC$JVMW\QY#@`[F`!TDV@.+6[M9.F27'U+$YR*J\TN:T=NI:(#E\4]00R,E/3
MI<-"/*-J^8Q&]Q_,[I+45M7.^_*=$:?V'E.N3ME;TV(7.DT/C$.DSGF%%20>
M3.)7Y(Z<?Z,4`$[6)?$.P`>N^?I[/;W9\?HL+K;S0BYCHH4%Q\N"%2-1YC4*
M3'Y-[>6*\W^MS&BLMX-N_.Y$-\W<1--02J\)H!%:(?L[<-:Z+KU-0;@RZQVA
MKAO+%=:;+RZX9!D\1LATG;\"1II[]8G[RDY#J29E<!??(!4,`F_,)0``M%1B
MMCNO<CKE^+KI9+E8S<P2D@H4!``@4`$J=5,52VYA>K3VN%DQ7;;;];KWTV1\
MR)^!D2G@1XQI!M5_='J1']3L;#W"M:SQL_?BI8?-<Z7P^LL'/=(#.GH/NPI)
M[8(DB2.Q<BC(*?W"E\C_`*[HW7B`!F&'#%,ZK;RYMFY=N-NL;G!#N"B6Y`0I
MG,B8T6<:;G;LRPJBLP%Y=<>H7VW-FW;*2IJ=I3V%..L0I9EW75"]S;+K+9N_
M;QUF)8%LL*NFUBL;6RY^JDBKY)^C69B5=/2+Q054Y3)3&%L>W%1W+X&<PZ%/
MQZ&=MEBL_.P:AKL8H++<VL!ZDT`]34&>T'S!1-9;8@[C?,AMO<"MM>3WF]VT
M\R\CII0"VN:AV@Z$A#J=%*A28K]FV;-],[&^9*_HO9%B2N8518%%QN-,4NS&
MK)C<UE-M,Q&%@>9VF2/$4>T8@L^D!E3:_:"F2;Q3.`E./)[I%)F]CPC%:ND:
MWEUXN*EH(,MI`;.32B$3]/IUG%8ZU6X'?.X&3T-6'.H.FA"09DD>KS1=?;I*
M+B;)N6R>AU`53MV;9^T[J?FR4U?A[`5]8)X9FUG/6B>96,60$@K-'(HB-=_M
MI=W,+,5G,*9B)@4X'*;UI6)4V,]PLIK\)Y-F9;N6KA;G-/J#FHT!VI>2`5)(
M+2T-(=J+UE_.S#MIC-#FK[Q>+DX$=0:40M<)E"@:`9:I-5&@])K]:D9I[=?Y
M@;/E6+(LF+QZ4ZG9N82)QMZF<E\7RIE?#[<?CF+D2<1*J]E]/#HI>Q#Z``_.
M56NLN_;W#+'1`%_YDDTX@G@?#P7S&L=V'WJCQ_N'GU]KE#`ZVDRU&US9?61'
M?[G[0UMLMIM.<^M<.P\="(7GJC@O9[%J:=UGY@^[%UL4HL"-E1N(`_"`%'OQ
M[#U#OGDP##KWB>;4G4@T$V6YHA)*"W.,U$I$>,S[(]7<3+K/EF`571'$AEXM
MP/!3U)L^.NT_13%=/[>;HK7;ZY/C\A;&Z?V9[@2)JV5<I-C&\&VKJ[(\^-^U
M2T"!C%*:V9.7`9Q(/0)L;CZ`(]]6AV36.Y850=RKF\_KJT[K<9@`D`].<0`%
M0;C*2[E"@)6>9C616W-JWMA1N:<)R(BOFI(;+J`#B3(#:W:=J#9M52D04+$;
MUS$/FASM7IT^UE;,"VI=Y+`,:(X+"XM;[["I8WVH2++)8P)"`JP(_;`/$1,J
M8G0>GK,7^MLE+_3_`/55&+A8>B(A*$$HFAU5P$CQD>$0N-T63-;G@PZJ=;[U
M0WI0FA:'.!UW)\)`)&HF#J;/S#=E[E].41L'45FV&HQU7IW*=E[YB7WX0<)>
M[1_%/'X'5L[,G$E!QY)+;L870KX9K,R^3-'W`H"`&*7E-IL`I*.\5N*7BA&Z
MXWT6VW..FNYQFO\`MQ);-R./@#%PJ^X5566:AR6S5@)M]E-QN(`UD0![3<0A
M\1IK'A*2LW;:RW[5.34U?EJW#=$T=*_L_<:.29ECS3IY6U,6$Q!*#0S&!.*@
M:-6<2-O>"9A;&AY>'_R3,H[`!``XRMYMV'V[D7FDO5#T['@"+<K2+H2'`!)K
ML7<"H`T()!6(C&[EG%RN-FJ[+=[O<+V_F!UP!+3;K?0%73"-#N8@!4>ITY-2
M/::UXV\E^6=N?E8^YTTQ5-7=G;"@5=P4(?6+?&)\=B8#&8&.>B$.$S'%U3EP
M`$S69,1$<T?43=<\>5?H/';)8PRQ,(N=E!<KB"%("M.T[B."[3IIPD</_7V0
MWG)FF]%;=>D`0$).2+Z0@TF(X/QZWC84KN>*51>]_;#P#:V"M,Y_KUK5?S;'
ME8/;QLMO.LTSVAG>/1_"1C\9BA0(8G@HH=1H,(_;/U[B?L[KV*CI+%UK&:&R
M/P/_`&ZX6WB`0HN*ZG@/`I[([^U][K*S):6RWZ]7L9HGYA;[E/XMQ:;<!Z=!
MND[U>I$3<=>-IM8JDVYJ%UH^Z&P7*./AB9[7EX.;^AD+$]-'9V=_CRYBB8CW
MB>7D!NNNNP$/IUBN'Y->\*O0OEC*.&HX$>!_`ZCW@[7F&(67-;,<8O7PG3RX
M+[/[8QGK2_=E_B_N5OU*V6E&7L90LPKVP9%JU;^6<Y9PVIU1!7N3GK"<=B=)
M90N,T>UD/_,\3&PO$WB8Y0VVZXQB_=BR?KC$6B@OX>.H6\`?WB%>THA"$N4:
MS:1NUPBV93EO:.[#"\I::ZQEO\A7DKPD)DD:@.:22/B:2UR-ANRY[MG(?BS>
MOD+<-O;HCEKV`F@^8=:PG(@S5444KV:VLA!L>&QM@-%?W29]Q(ZN'B]`\B]$
M7$0`0,40&<LEJPZ@[L#ML;/9W8^Q.62YI+G.V!^XO""8,QM;ZI`B0BN7Z[9@
M.S_]3Q>[QU_;NVAP%O3<6_`B!LOB4HLQQC0VC+*O&2_(!M'03O=4@=H/%M5*
MEE=:8&6Q,0!`G:?"9$'U3S+YR*1$.83"+L(B8`Z_@$W><7VTXO3=O;3D+*%H
MYCKTYIX%P;N`:7!2`HE(I-`28U'&[GDE5W,N^+U]7NLC;.TCR4@!P\"`225T
M\$G0AMVSVRR?C6H2]%[^D6)8D@WD_I9/'8&"$@YS"'N]W2*+BQ^D7$D;!--J
M`H`S@`^)A`.P[ZT1^%X0[NC5V-U$MB;92X:R*(LM9%(RZDSC,JSM'1WWK`Z\
M;T&DH)B9`]FI32+7GKO+M/Y=]LXQBV%8U8'-J'2F4,CJYX9(W)R=2`I09SO6
M5'9&/@7Z^G0_[0,'7*9SKGTGLG9*L4G*KAUJX?&W<WV(K#PE/ZEB]MMG5.^%
MYI!5NH%LU!)I`/#Q*>7XHB4/EMZ6Q=]#T3"+AF>7-9UKS\SM>:ZA9PXC&VN<
MP:8V,C!DD+V`@$7_`'*/F`'Z'Q[`/3L1$=/I+!8\=RBLKK'1CH%RP<W))2TT
M^S27%(S2Z9+>\AQBCH[W6)D%NS?II*:HOOX^Z-4:9L"R:7^1V2Z;/%H6);]:
MS34]JV/C+_9J["]R6#2Q.T7ZO7MC0=X['8T1:.28K3[D0JG?2Q1`H%`W,2NU
MLH+_`-JOUW3T;*&]\N\FWNV@[2W9N"-)/!"/4=%":1M=BNEZL/=<8`:PUU@?
M9NH#<BJ';=="5/L]0U6-?.93&V0XA&;5Z0Z'13(]JEV.UX<7?)Q&91"9!YK-
M3E&TWVT&%&^(.F_LYB9!8]*H\]YCJ&`;L%B9V>/AXX)#$ON*U-?5%M?1$_Q6
M@@H0CB!^7%"D]P13,(`4#C&49/3T%./DJQ"QTP=)$K<?LX:?=$*9.5%IB:76
M6LTCCXX^UPO6JIHW&B.3H:+Q^;$*_3=C@4>`3F$P?KQ#KKQ*3-#OKH.6C^;M
MPZ%Z@P3N9)'%4!)G[#KH/&*N/E:OYN]D;BB6VW::<0!)25\M>*1PI'EUY%<*
MT(1B93>_U9-HW,+`UVE33G@UA`9^PLO_`'40CCZ7RE+#(U2D`Q1`0\0'#*/Y
M\\2AQ2<RNK74=>6O&0,=MN0DC@2-KY<$XR1'!)1]5(M%&RKH7[>A.`-N]H$P
M..OOD?"+U4=%H^ZYKE84>9FAEAV-C.<.J)D:L4F"VI1$'KSD4Q23+Y^!K/D+
M*D<@@7H[*W8!OJ81&@7[GUM+S/D+FO700ZO)3XT,@$1&@*JE7$Z)&FXU34CV
MB\6_;T+2@"Z-(F5UF=%`E%K54ONI"F`BGWUZEZ].OP``'KKE:BX1C?5GQNW7
MKQ(+MSZ!WCD\9P;^E;G.)B-DTM"[.E#?*<H,C[KXSR%*31'%1>A*Z=^0M(D'
MQ#L`,!!-L%Q[HV'(*&@Y646,.-M9M"5[VM0HH3:0UI02).@$TC"+#VIRC%:F
MMYF,Y(6=0F5MS2>,U#D**BR]BK''<_B)@:>O$7H6O[EET2-C7BS;&638CO&V
M::3>U[29$<4S2]R161J&1:2HJ@!OT)"^'B;Q#KHPG^J3O)=&Y,Z_5M(Q[C9N
MG-"EH#)<?5N.I5!J@2/NJ[*T!QD8M9ZLM;UH7(E!K.4D\IJ0=2L61VPU!D6T
M[=0F)F77D0!>C;(A]OXV4TUNRN2DJL:#E\V%V%%W?E2,4>(97+$S:`F\ON^J
M@@0.ZKB&5TN*NK7<JA#W5[2TJ]P0%"=`X$R$RCO/5;3GN%<_-30GF5VTV[F"
MOT7U3151.(\/PA6S/CAGUQL;[5]J;92&:Z^2.Y/ZPN%>.=8-)YWBD";?OM.%
M,MK%D:8LL<3R"_;*4&43E*/8"'?7+':^Y]+CU<Z^62R\IE\-FZ=NWZ^D`.<`
M`N@"%R(!ZI`16[KVINM]HNE7J\O-AZSU#;M.X!3+YXE9*2#M4$E$UCG2KXT&
M&;VGM1(Y%;[YE4CN'AQ+,N6EBPYA*Y&D\%8TV:-/L6ML<D9&P'C4B3!T(/M0
ME*KZ>0E`>>>F[LU]MM%DH:*B;^H<;!%ON)<5:'&0+`K24&I,IEJ@D1[>;VBH
MJB^7FX55:X6'(D-PMX$B1,%KN`4^\3X&/EF_'E-;(P*AK39':"27A0M(OL>D
MK'6)ZU984[SMR@0)JP$EJ3Z/R40E",6''(*I46EH!W,4#*AV`]?`[F4=KK*R
MY8E9V6V]W$'_`+FXN+02-R*T@*@DNT$#TN`2.'=K>?=J6CLF57AUPLEN,F(F
MZ2@5\W;@!I-4U*J8G"@]09#26R.R.P6=<F;,\C9+-B.?+HCEP5B8&_!=*_80
MC4*497?'6,L<,5A[34*/D`G`/7\0A;_F%)D.-6C&?D6L%K:0UZDE'(7$M0`3
M`(F5UE$WC6"U>/Y/>,H-:7&YE2$1$T^GU3CV&XVM+[M=6#=5[7;KO3[2K,(E
M+GO-98BQ2=R?A@LA892PXZ82'Q(S#CR-DQ#>1`$PE+]![YU8+E-)A%Y%^-"+
MAS1P+B!]:`C0&:'3VQ[\\Q"KS:R&RMK30-/$`'\0>/"+.,38^8D4PFURD(.<
MDQVD,++E'M">`&8Y`B5,SI[(4YL<G9_S>`&$OX=]#Z5.H=3FK)(2>B_CI]$B
MWTU-4T]'\H2"[QC-W6[49/1B4;+W_/=F<J71:U\EUMRY4Y/7T*AC3A29F4>W
M]QFZ+VP_9,TX*:>;G`=O*04OS@/J/H.EY1EP[B4%FQ.BLP#[:-M!M<YQ&[;(
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MXGEDH&_Z`@-(0#VG4+K-V3`,BL-'TBCO3N@@$AH9M<BK_KQ,3*(&RT$I1R:=
MT+D55,^W;4KL1)GI7;9^GDO=G=IAK3"'B"6#/8^+%D3.$NS`^F61R<=`Q5"%
M_B,<"]B'J`\WGN!R;GS[*QM`UK+4&AJ.+@6M(^+<T)H@/J(,UUA8^V-38J.]
MTW5W..0*241"0?.>N@`!'FACY0?1&9?UWIN_[YV+S+ZEFOL1E47J10*Y9:^<
MDU)1'R1]^?)^\LDBRT9V_+I)AT*:32B!C&.)>_(17+.Z9F-5^+8U0MMG+N)W
M$[W/*A"$!:$`D9(G`36.;7VYJG9-19-E%W=<G6Y1;VEK6HNI<A]1G/53K$J[
M8ZIR#8UYI260"[Y;K_8M(3!YE$8FD19F&39N:V2%A.PR"/9##)$U6)=BSB&P
MS&$Q#@()]=`/J:&PW,:;$V5U)74+;E:;DUH+2Y`HGJA1%/#]L3>8X;59764-
M=0UIMUYMY)!`74>WQ^]/*(58-`)!*[NC=_[97YG;.R>NX=+X;6,54K5CJZLX
MFVSMI/'9@\GCC!ER<K\_2*/#X'4,N4B8?E``#KDQS<^I:*SNQ?#*!MK!<USB
M'ESCIZ5<T(`9`3&U1M"E('E=M:RLR1F39G7]2Y]#)OI-``?$['>]"`O]Z,V_
MD!U@D.G'QNW;56#LUF2.@,'+BS94=,RR&Q/`F[;[Y=\7DY&0EMA(O?Y*,7Q\
MG,5+_P!0"@D'U`?`>M9[6Y/39GW/H+XZS,.2$`ON0>Y`=I`(800%(1"DIJXB
M>0]U\/Y^!]JJ^QLO)-C!`H+?M"_^P:_XOB<`'+X2FBQI%DZ<NTWN!KVXUWVD
MD%1.EG4A!*QGP1V'PFS(_-(E'@)EQ]ZC3O(3'%BD21EO'W8QG<0`H`!1``$<
MP_78L]F&#Y39A<&6Z].Y@5SF%>((3X9DE9"0+9+&K/P>JO%X.<8M=W6]UQLX
M:FUI&@(=,R3WJ"1PB'$?B.S&G6J(ZQ->T<BPZ\A-VX]VQW-<JOB6?)B/^+(5
MI(SM+^\*2$J;X3'D.48XG$J8K#T4P]`7J<'>AWZE_571F=:Z+T]=Y(VH/5-J
M#02!3CNXQ#,['\NDQ&CPRAN[A9K?>>H+MF0-R-UD`I,_'0Z1*SUH3=39LQ+]
MJ:IW%=(18EB5ZQUA+<63TA#9U&"LL>Q^T#QIH-)X>,;,,A\G$PK"ZB<1,41$
MIO6%I^Y%F=C-%BM\LAYEEMY+F_S[VB9)5=I1R%"?%9!4B7YO;'(N1EE;FEEO
M(Y5[KF@%;>#)``"2[0)J0OF91XR7_$]'%J+J"J:UORP:]?ZPO'^YW/GN='8E
M,W2R[Z(B0$YQ.VG(Q\=`^0!Q]$VPZ`%*/X]>LA2=YK@Z]5U[JZ1I%PLW3'`$
M#;;Y*S0J3JIVE2A\O)<>RU`_&Z*RV6K-"ZWW@7)I*G\P`1KE#@FT2`)(`X'2
M+243JT\5W;DRV)N2SOZVWU-H6U5>G+\2&MM;L$,K!B=U'[%A<1@C8_R@,4II
M0^9K@[N"CJL=58Q`*`%3'NBWS+&UEHI,9LU"RW6-KM^T$N<7H1N<Z1/I0-!'
MI`"%``+MC.'U5HO%5DMYK77&]D;0=H:&M&@#=!^,Y3B^/*M%]AQ"(:MJH('>
M,14@UB-`.\?,Z-3YCIDRAP\W"=X^ZI/+([-*Z93`DLCD)AT?L/0/'KZ]>^QW
MROL%:*^W%'A>"JO`A1]A'X1"7ZPV;(:+I]Z"@_5]/MB'ZVU79:F:D6B"6E;+
M.B;H<UP!6M'5_<Q3]?)_D3[665(7GLX?E\U1$/\`7DQ<\NN%Y(?7TK"X:^DI
M]0WR/FA/W1`VO!:.P4?R5OK;P>5X[_\`I^XQYR;Z+53:CN5ULZ4V),?N&'WG
M#RG2)Q=MEWFSBQ@$E3KV*PXSUUCF#^,0Z-Z=`'0<D[3W%O\`9J,T-H+?X>NA
M\?,Z)PX>R4>"[=LK'=ZSYZ\3=X2\/I[?MBZ#?@-[1@8;=@8N,WM[=BEQ<3$Q
MB@3#P\%(I2D(4/$I2D*1,`#_`,CRC<8T>7)'@([CG$<PXA#B$.(0XA#B$.(0
MXA#B$.(1U6;A8+GBK86=B8N=@91>LK%R\0N?A99!Z[*9-0#)G`!*'U`0_P`.
M?,J?Q!$<Q]T<=##11QT$2H(8X>.-C8_H`%`![`"^@=!Y#Z?X\^HXCG<0AQ"'
M$(<0AQ"/./;"QOR"*#VTMKNACB&3C(.>$FX`0X!_&4JQ5"^7KU^/?.WD5%72
MA:,ELD4%(\U32TE4@K`"V.;A86`V8B6"VX>-@8.*3QQ<3$Q"86%BD*!O0J:9
M2)E*/E]"@'^7X\Z^,>B7('E';<XCF'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ
M"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
